Symbols / LYRA $0.50 +0.00%
LYRA Chart
About
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 878.57K |
| Enterprise Value | 10.20M | Income | -32.95M | Sales | 600.00K |
| Book/sh | -2.63 | Cash/sh | 12.43 | Dividend Yield | — |
| Payout | 0.00% | Employees | 30 | IPO | — |
| P/E | — | Forward P/E | -0.50 | PEG | — |
| P/S | 1.46 | P/B | -0.19 | P/C | — |
| EV/EBITDA | -0.32 | EV/Sales | 17.00 | Quick Ratio | 2.33 |
| Current Ratio | 2.43 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -22.90 | EPS next Y | -0.99 | EPS Growth | — |
| Revenue Growth | -87.20% | Earnings | 2025-11-12 16:00 | ROA | -33.08% |
| ROE | -4.04% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -250.32% | Profit Margin | 0.00% | Shs Outstand | 1.77M |
| Shs Float | 365.70K | Short Float | 1.10% | Short Ratio | 0.35 |
| Short Interest | — | 52W High | 37.50 | 52W Low | 0.48 |
| Beta | 0.06 | Avg Volume | 102.53K | Volume | 1.04M |
| Target Price | $16.00 | Recom | None | Prev Close | $0.49 |
| Price | $0.49 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$16.00
Mean price target
2. Current target
$0.50
Latest analyst target
3. DCF / Fair value
$-205.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.50
Low
$16.00
High
$16.00
Mean
$16.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-14 | reit | HC Wainwright & Co. | Neutral → Neutral | $16 |
| 2025-06-10 | main | HC Wainwright & Co. | Neutral → Neutral | $16 |
| 2025-03-14 | reit | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2024-08-15 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-08-15 | reit | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2024-06-20 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-05-07 | down | HC Wainwright & Co. | Buy → Neutral | $2 |
| 2024-05-07 | down | Jefferies | Buy → Hold | $1 |
| 2024-05-06 | down | BTIG | Buy → Neutral | — |
| 2024-05-01 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-03-25 | main | B of A Securities | Buy → Buy | $11 |
| 2024-03-22 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-10-02 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-09-12 | main | B of A Securities | Buy → Buy | $15 |
| 2023-08-31 | init | HC Wainwright & Co. | — → Buy | $12 |
| 2023-02-07 | main | BTIG | — → Buy | $20 |
| 2022-05-24 | init | Cantor Fitzgerald | — → Overweight | $15 |
| 2020-05-26 | init | B of A Securities | — → Buy | $21 |
| 2020-05-26 | init | Jefferies | — → Buy | $24 |
- Lyra Therapeutics Withdraws Nasdaq Appeal, Faces Imminent Delisting - TipRanks Mon, 16 Mar 2026 21
- Lyra Therapeutics to raise up to $15M via registered direct offering and concurrent private placement, stock falls 22% - MSN Fri, 13 Mar 2026 09
- Can Workday's Wellness Tie-Up With Lyra Health Aid the Stock? - Yahoo Finance Wed, 11 Mar 2026 15
- According to the latest disclosure from the U.S. Securities and Exchange Commission, trading of Lyra Therapeutics Inc (stock code: LYRA) shares will be officially suspended at the market open on March 17, 2026. - Bitget Mon, 16 Mar 2026 06
- Lyra Therapeutics Received Notice of Delisting - TradingView Mon, 16 Mar 2026 20
- (LYRA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily Sun, 15 Mar 2026 09
- Lyra Therapeutics Inc withdraws appeal of Nasdaq delisting determination - SEC filing - marketscreener.com Mon, 16 Mar 2026 21
- New Alchelyst platform targets smoother private-market investing - Stock Titan hu, 12 Mar 2026 13
- $LYRA stock is down 46% today. Here's what we see in our data. - Quiver Quantitative Mon, 12 Jan 2026 08
- BBNX,LYRA Volatility & Greeks - Finviz hu, 12 Mar 2026 21
- Lyra Therapeutics Provides Corporate Update - GlobeNewswire Mon, 12 Jan 2026 08
- Lyra Therapeutics Stock Under Pressure as LYR-210 Development Halted—What Investors Need to Know - AD HOC NEWS Fri, 13 Mar 2026 11
- Sinus drug work halted at Lyra Therapeutics as most of 28 staff exit roles - Stock Titan Mon, 12 Jan 2026 08
- Why Is Lyra Therapeutics Stock (LYRA) Down Today? - TipRanks Mon, 12 Jan 2026 08
- Lyra Therapeutics Inc expected to post a loss of $7.14 a share - Earnings Preview - TradingView Mon, 09 Mar 2026 11
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1702 | 5726.0 | — | Sale at price 3.36 per share. | PALASIS MARIA | Chief Executive Officer | — | 2026-01-06 00:00:00 | D |
| 1 | 769 | 2587.0 | — | Sale at price 3.36 per share. | CAVALIER JASON | Chief Financial Officer | — | 2026-01-06 00:00:00 | D |
| 2 | 45875 | 182515.0 | — | Sale at price 3.90 - 4.31 per share. | PERCEPTIVE ADVISORS LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-13 00:00:00 | I |
| 3 | 70390 | 344219.0 | — | Sale at price 4.54 - 5.18 per share. | PERCEPTIVE ADVISORS LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-10 00:00:00 | I |
| 4 | 1565 | 13944.0 | — | Sale at price 8.91 per share. | PALASIS MARIA | Chief Executive Officer | — | 2025-07-10 00:00:00 | D |
| 5 | 684 | 6094.0 | — | Sale at price 8.91 per share. | CAVALIER JASON | Chief Financial Officer | — | 2025-07-10 00:00:00 | D |
| 6 | 800000 | nan | — | — | PALASIS MARIA | Chief Executive Officer | — | 2025-01-08 00:00:00 | D |
| 7 | 420000 | nan | — | — | CAVALIER JASON | Chief Financial Officer | — | 2025-01-08 00:00:00 | D |
| 8 | 300000 | nan | — | — | PALASIS MARIA | Chief Executive Officer | — | 2024-10-16 00:00:00 | D |
| 9 | 100000 | nan | — | — | CAVALIER JASON | Chief Financial Officer | — | 2024-10-16 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | -276.36K | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.00 |
| NormalizedEBITDA | -24.65M | -63.66M | -52.61M | -42.61M |
| TotalUnusualItems | -35.62M | -1.59M | -1.32M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -35.62M | -1.59M | -1.32M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -93.44M | -62.68M | -55.28M | -43.51M |
| ReconciledDepreciation | 471.00K | 278.00K | 1.07M | 1.00M |
| EBITDA | -60.26M | -65.25M | -53.92M | -42.61M |
| EBIT | -60.73M | -65.53M | -54.99M | -43.62M |
| NetInterestIncome | 2.95M | 4.50M | 1.04M | 102.00K |
| InterestIncome | 2.95M | 4.50M | 1.04M | 102.00K |
| NormalizedIncome | -57.82M | -61.09M | -54.24M | -43.51M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -93.44M | -62.68M | -55.28M | -43.51M |
| TotalExpenses | 62.27M | 67.09M | 56.35M | 43.90M |
| TotalOperatingIncomeAsReported | -96.35M | -67.12M | -56.31M | -43.62M |
| DilutedAverageShares | 1.30M | 996.09K | 604.71K | 259.72K |
| BasicAverageShares | 1.30M | 996.09K | 604.71K | 259.72K |
| DilutedEPS | -71.50 | -63.00 | -91.50 | -167.50 |
| BasicEPS | -71.50 | -63.00 | -91.50 | -167.50 |
| DilutedNIAvailtoComStockholders | -93.44M | -62.68M | -55.28M | -43.51M |
| NetIncomeCommonStockholders | -93.44M | -62.68M | -55.28M | -43.51M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -93.44M | -62.68M | -55.28M | -43.51M |
| NetIncomeIncludingNoncontrollingInterests | -93.44M | -62.68M | -55.28M | -43.51M |
| NetIncomeContinuousOperations | -93.44M | -62.68M | -55.28M | -43.51M |
| TaxProvision | 39.00K | 59.00K | 13.00K | 0.00 |
| PretaxIncome | -93.40M | -62.62M | -55.27M | -43.51M |
| OtherIncomeExpense | -35.62M | -1.59M | -1.32M | |
| SpecialIncomeCharges | -35.62M | -1.59M | -1.32M | 0.00 |
| ImpairmentOfCapitalAssets | 24.72M | 1.59M | 1.32M | 0.00 |
| RestructuringAndMergernAcquisition | 10.90M | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | 2.95M | 4.50M | 1.04M | 102.00K |
| InterestIncomeNonOperating | 2.95M | 4.50M | 1.04M | 102.00K |
| OperatingIncome | -60.73M | -65.53M | -54.99M | -43.62M |
| OperatingExpense | 62.27M | 67.09M | 56.35M | 43.90M |
| ResearchAndDevelopment | 43.77M | 48.03M | 38.80M | 29.69M |
| SellingGeneralAndAdministration | 18.50M | 19.06M | 17.56M | 14.21M |
| GeneralAndAdministrativeExpense | 18.50M | 19.06M | 17.56M | 14.21M |
| OtherGandA | 18.50M | 19.06M | 17.56M | 14.21M |
| TotalRevenue | 1.53M | 1.56M | 1.36M | 285.00K |
| OperatingRevenue | 1.53M | 1.56M | 1.36M | 285.00K |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 1.31M | 1.14M | 636.55K | 260.14K |
| ShareIssued | 1.31M | 1.14M | 636.55K | 260.14K |
| TotalDebt | 34.38M | 26.88M | 4.18M | 1.45M |
| TangibleBookValue | 11.59M | 89.42M | 80.75M | 34.32M |
| InvestedCapital | 11.59M | 89.42M | 80.75M | 34.32M |
| WorkingCapital | 30.39M | 85.22M | 86.36M | 29.67M |
| NetTangibleAssets | 11.59M | 89.42M | 80.75M | 34.32M |
| CapitalLeaseObligations | 34.38M | 26.88M | 4.18M | 1.45M |
| CommonStockEquity | 11.59M | 89.42M | 80.75M | 34.32M |
| TotalCapitalization | 11.59M | 89.42M | 80.75M | 34.32M |
| TotalEquityGrossMinorityInterest | 11.59M | 89.42M | 80.75M | 34.32M |
| StockholdersEquity | 11.59M | 89.42M | 80.75M | 34.32M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 33.00K | 10.00K | 0.00 |
| OtherEquityAdjustments | 33.00K | 10.00K | ||
| RetainedEarnings | -404.79M | -311.36M | -248.68M | -193.40M |
| AdditionalPaidInCapital | 416.32M | 400.69M | 329.39M | 227.70M |
| CapitalStock | 65.00K | 57.00K | 32.00K | 13.00K |
| CommonStock | 65.00K | 57.00K | 32.00K | 13.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 54.75M | 53.18M | 29.21M | 20.55M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 42.12M | 33.58M | 14.74M | 2.31M |
| NonCurrentDeferredLiabilities | 11.86M | 12.14M | 14.08M | 1.93M |
| NonCurrentDeferredRevenue | 11.86M | 12.14M | 14.08M | 1.93M |
| LongTermDebtAndCapitalLeaseObligation | 30.26M | 21.45M | 667.00K | 379.00K |
| LongTermCapitalLeaseObligation | 30.26M | 21.45M | 667.00K | 379.00K |
| CurrentLiabilities | 12.63M | 19.60M | 14.47M | 18.25M |
| OtherCurrentLiabilities | 4.82M | 1.23M | 659.00K | 633.00K |
| CurrentDeferredLiabilities | 398.00K | 1.66M | 1.27M | 9.79M |
| CurrentDeferredRevenue | 398.00K | 1.66M | 1.27M | 9.79M |
| CurrentDebtAndCapitalLeaseObligation | 4.12M | 5.43M | 3.51M | 1.07M |
| CurrentCapitalLeaseObligation | 4.12M | 5.43M | 3.51M | 1.07M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.43M | |||
| PayablesAndAccruedExpenses | 3.29M | 11.27M | 9.03M | 6.75M |
| CurrentAccruedExpenses | 2.11M | 8.14M | 6.41M | 3.62M |
| Payables | 1.18M | 3.13M | 2.62M | 3.12M |
| AccountsPayable | 1.18M | 3.13M | 2.62M | 3.12M |
| TotalAssets | 66.35M | 142.60M | 109.97M | 54.87M |
| TotalNonCurrentAssets | 23.32M | 37.78M | 9.14M | 6.95M |
| OtherNonCurrentAssets | 1.99M | 2.50M | 4.67M | 1.09M |
| NetPPE | 21.33M | 35.28M | 4.47M | 5.86M |
| AccumulatedDepreciation | -4.13M | -1.92M | -4.17M | -3.88M |
| GrossPPE | 25.46M | 37.20M | 8.64M | 9.74M |
| Leases | 486.00K | 461.00K | 397.00K | 2.11M |
| ConstructionInProgress | 0.00 | |||
| OtherProperties | 23.85M | 35.97M | 7.25M | 6.65M |
| MachineryFurnitureEquipment | 1.12M | 767.00K | 998.00K | 976.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 43.02M | 104.82M | 100.83M | 47.92M |
| OtherCurrentAssets | 2.45M | 2.07M | 2.94M | 2.17M |
| PrepaidAssets | 2.17M | |||
| CashCashEquivalentsAndShortTermInvestments | 40.58M | 102.75M | 97.89M | 45.75M |
| OtherShortTermInvestments | 0.00 | 80.40M | 65.34M | 0.00 |
| CashAndCashEquivalents | 40.58M | 22.35M | 32.55M | 45.75M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -72.35M | -64.35M | -43.55M | -29.20M |
| IssuanceOfCapitalStock | 8.82M | 69.24M | 100.50M | 0.00 |
| CapitalExpenditure | -2.34M | -1.05M | -164.00K | -3.38M |
| EndCashPosition | 42.57M | 23.75M | 33.94M | 46.08M |
| BeginningCashPosition | 23.75M | 33.94M | 46.08M | 74.92M |
| ChangesInCash | 18.82M | -10.20M | -12.13M | -28.85M |
| FinancingCashFlow | 8.53M | 65.69M | 96.26M | 359.00K |
| CashFlowFromContinuingFinancingActivities | 8.53M | 65.69M | 96.26M | 359.00K |
| NetOtherFinancingCharges | -290.00K | -3.65M | -4.25M | -245.00K |
| ProceedsFromStockOptionExercised | 3.00K | 103.00K | 8.00K | 604.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 8.82M | 69.24M | 100.50M | 0.00 |
| CommonStockIssuance | 8.82M | 69.24M | 100.50M | 0.00 |
| InvestingCashFlow | 80.31M | -12.58M | -65.01M | -3.38M |
| CashFlowFromContinuingInvestingActivities | 80.31M | -12.58M | -65.01M | -3.38M |
| NetInvestmentPurchaseAndSale | 82.64M | -11.54M | -64.84M | 0.00 |
| SaleOfInvestment | 130.59M | 110.89M | 0.00 | |
| PurchaseOfInvestment | -47.95M | -122.42M | -64.84M | 0.00 |
| NetPPEPurchaseAndSale | -2.34M | -1.05M | -164.00K | -3.38M |
| PurchaseOfPPE | -2.34M | -1.05M | -164.00K | -3.38M |
| OperatingCashFlow | -70.01M | -63.30M | -43.38M | -25.82M |
| CashFlowFromContinuingOperatingActivities | -70.01M | -63.30M | -43.38M | -25.82M |
| ChangeInWorkingCapital | -6.35M | -4.88M | 4.55M | 13.92M |
| ChangeInOtherWorkingCapital | -1.53M | -1.56M | 3.64M | 11.71M |
| ChangeInOtherCurrentLiabilities | 966.00K | -1.21M | 763.00K | -986.00K |
| ChangeInOtherCurrentAssets | 2.46M | -4.93M | -1.44M | 446.00K |
| ChangeInPayablesAndAccruedExpense | -7.86M | 1.94M | 2.36M | 3.59M |
| ChangeInAccruedExpense | -5.97M | 1.49M | 4.77M | 1.24M |
| ChangeInPayable | -1.89M | 450.00K | -2.41M | 2.35M |
| ChangeInAccountPayable | -1.89M | 450.00K | -2.41M | 2.35M |
| ChangeInPrepaidAssets | -380.00K | 867.00K | -764.00K | -847.00K |
| StockBasedCompensation | 6.72M | 5.89M | 5.45M | 2.77M |
| AssetImpairmentCharge | 24.86M | 1.59M | 1.32M | 0.00 |
| AmortizationOfSecurities | -2.28M | -3.50M | -492.00K | 0.00 |
| DepreciationAmortizationDepletion | 471.00K | 278.00K | 1.07M | 1.00M |
| DepreciationAndAmortization | 471.00K | 278.00K | 1.07M | 1.00M |
| Depreciation | 471.00K | 278.00K | 1.07M | 1.00M |
| NetIncomeFromContinuingOperations | -93.44M | -62.68M | -55.28M | -43.51M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LYRA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|